Replimune Group (NASDAQ:REPL) Trading Down 6.6% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) was down 6.6% during mid-day trading on Monday . The stock traded as low as $10.44 and last traded at $10.2610. Approximately 245,496 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 4,548,816 shares. The stock had previously closed at $10.99.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of recent research reports. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday, April 10th. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a research report on Friday, June 26th. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Replimune Group has a consensus rating of “Hold” and a consensus target price of $8.12.

Replimune Group Trading Down 8.1%

The firm has a fifty day simple moving average of $8.02 and a two-hundred day simple moving average of $7.38. The stock has a market cap of $847.79 million, a PE ratio of -2.98 and a beta of 0.86. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts expect that Replimune Group, Inc. will post -2.29 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after acquiring an additional 6,653 shares during the last quarter. Millennium Management LLC increased its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after acquiring an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Rhumbline Advisers raised its position in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.